The combination of erlotinib and onartuzumab versus erlotinib alone was studied in second line therapy of NSCLC patients [37]: among 137 patients randomized, 52% were MET positive at immunohistochemistry (IHC) analysis and experienced a statistically significant reduction in the risk of disease progression by the addition of onartuzumab, (median, 1.5 vs. 2.9 months; HR: 0.53; p = 0.04), while in MET IHC-negative tumors onartuzumab was detrimental. Here, MET is linked to non-small cell lung carcinoma.